Antiangiogenic therapy is a promising new strategy to inhibit @entity5 growth and formation of @entity3 . @entity7 ( @entity7 ) is known to be the most important proangiogenic factor, necessary for the development of new @entity5 vessels. Specific inhibitors of the @entity7 receptor @entity669 kinases, like @entity17482 / @entity17482 (PTK/ZK), have shown antitumoral and antiangiogenic activity in several animal models. Ongoing early clinical trials with antiangiogenic compounds reveal the need for diagnostic methods to detect their biological activity. Pro-angiogenic growth factors like @entity7 and bFGF (basic fibroblast growth factor), soluble variants of proangiogenic receptors like sFLT-1 and sTIE-2, as well as endothelial activation markers like sE-Selectin, can be measured in the serum and plasma of @entity1 by the ELISA technique. They were detected in various malignant diseases to assess their use as surrogate markers in @entity5 angiogenesis. In different clinical Phase I trials with antiangiogenic compounds, these soluble markers were used to detect dose levels for biological activity. Soluble markers of @entity5 angiogenesis can be used as prognostic markers in various @entity5 like @entity694 or @entity1582 . Furthermore, they correlated with disease activity, prognosis and imaging techniques for the detection of vascular changes. In clinical Phase I trials with specific inhibitors of the @entity7 receptor @entity669 kinases, @entity7 serum levels increased in @entity1 treated with higher doses, indicating increasing @entity5 . Taking results from imaging techniques such as dynamic enhanced MRI into account, optimal doses for biological activity could be concluded. New biological treatment techniques will need new diagnostic methods to assess their specific biological activity in @entity1 . Soluble markers and imaging techniques are useful tools for the detection of @entity519 under antiangiogenic treatment. Nevertheless, these techniques are still experimental. Therefore, further clinical evaluation is necessary.

Soluble markers for the detection of XXXX under antiangiogenic treatment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumor hypoxia', 'malignancies'] @entity17482 :: ('MESH:C404768', 'Chemical') :: ['PTK787', 'ZK222584'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']
@entity519 :: (MESH:D000860,Disease) :: ['hypoxia']
